Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Up 5.8% in January

Atossa Therapeutics, Inc. (NASDAQ:ATOS) was the recipient of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 9,250,000 shares, a growth of 5.8% from the January 15th total of 8,740,000 shares. Based on an average daily volume of 876,500 shares, the short-interest ratio is presently 10.6 days.

Analyst Upgrades and Downgrades

ATOS has been the subject of several recent research reports. Ascendiant Capital Markets raised their price target on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. StockNews.com cut Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, November 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Atossa Therapeutics in a report on Thursday, January 30th.

Atossa Therapeutics Stock Up 1.9 %

NASDAQ:ATOS opened at $0.83 on Tuesday. Atossa Therapeutics has a 52-week low of $0.72 and a 52-week high of $2.31. The business’s 50-day moving average price is $0.94 and its 200 day moving average price is $1.22.

Institutional Trading of Atossa Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN grew its position in Atossa Therapeutics by 30.7% during the fourth quarter. Wells Fargo & Company MN now owns 71,720 shares of the company’s stock valued at $68,000 after purchasing an additional 16,853 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Atossa Therapeutics in the third quarter worth $29,000. Barclays PLC raised its holdings in shares of Atossa Therapeutics by 14.5% during the fourth quarter. Barclays PLC now owns 191,954 shares of the company’s stock worth $181,000 after acquiring an additional 24,236 shares in the last quarter. XTX Topco Ltd boosted its position in Atossa Therapeutics by 101.2% during the third quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock valued at $75,000 after purchasing an additional 24,951 shares during the last quarter. Finally, Gallagher Capital Advisors LLC purchased a new position in Atossa Therapeutics in the fourth quarter valued at about $25,000. 12.74% of the stock is owned by hedge funds and other institutional investors.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.